Steba Biotech S.A.
Quick facts
Marketed products
- TOOKAD VTP · Oncology
TOOKAD VTP is a vascular-targeting photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy tumor vasculature and induce tumor necrosis.
Phase 3 pipeline
- padeliporfin VTP · Oncology
Padeliporfin VTP is a photosensitizer that selectively targets and destroys cancer cells upon activation by light. - TOOKAD® Soluble · Oncology
TOOKAD Soluble is a vascular-targeting photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy tumor vasculature.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Steba Biotech S.A.
What are Steba Biotech S.A.'s marketed drugs?
Top marketed products include TOOKAD VTP.
What is Steba Biotech S.A.'s pipeline?
Steba Biotech S.A. has 2 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include padeliporfin VTP, TOOKAD® Soluble.
Related
- TOOKAD VTP · Oncology
- Sector hub: All tracked pharma companies